AU Patent

AU2023201010A1 — Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Assigned to Atnx Spv LLC United States · Expires 2023-03-23 · 3y expired

What this patent protects

The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N benzylacetamide, and methods of preparing and using same.

USPTO Abstract

The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N benzylacetamide, and methods of preparing and using same.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023201010A1
Jurisdiction
AU
Classification
—
Expires
2023-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Atnx Spv LLC United States
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.